글로벌 혈액 응고 인자 시장 – 2030년까지의 산업 동향 및 예측

혈액 응고 인자 시장 분석 및 규모

뇌졸중 유병률 증가, 신약 및 치료법 개발을 위한 연구 개발 활동 급증, 의료 인프라 개발 지출 증가는 글로벌 혈액 응고 인자 시장 성장에 기여하는 주요 요인입니다. 교통사고 유병률 증가는 시장 성장을 촉진하는 주요 요인입니다. 의료 인프라 개발에 대한 지출 증가와 심혈관 질환 및 혈액 장애 발생률 급증도 시장 성장을 촉진하는 다른 요인입니다. 개인의 가처분 소득 증가와 실험실 자동화에 대한 수요 증가는 수익성 있는 시장 성장 기회를 창출하는 다른 간접적인 결정 요인입니다.

Data Bridge Market Research는 2022년에 5,687.25백만 달러였던 글로벌 혈액 응고 인자 시장이 2030년까지 9,4578.36백만 달러에 도달할 것으로 예상되며, 2023년에서 2030년까지의 예측 기간 동안 8.70%의 CAGR을 보일 것으로 분석했습니다. "임상 실험실 분석기"는 이러한 유형의 분석기에 대한 수요가 높아 글로벌 혈액 응고 인자 시장의 제품 부문을 지배하고 있습니다. 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

혈액 응고 인자 시장 범위 및 세분화

시장 정의

혈액 응고 인자는 혈액 응고 또는 응고 과정에서 중요한 역할을 하는 혈액에 존재하는 단백질입니다. 이러한 인자는 함께 작용하여 혈전을 형성하여 출혈을 멈추고 상처 치유를 촉진합니다. I에서 XIII까지 번호가 매겨진 여러 혈액 응고 인자가 복잡한 반응 연쇄에 관여합니다. 이러한 혈액 응고 인자는 적절한 혈전 형성을 보장하고 과도한 출혈을 방지하기 위해 조정된 방식으로 작용합니다. 이러한 인자의 결핍이나 이상은 출혈 장애 또는 응고 장애로 이어질 수 있습니다.

글로벌 혈액 응고 인자 시장 역학

운전자

• 출혈 장애의 증가하는 유행

The rising incidence of bleeding disorders such as hemophilia and von willebrand disease is a significant driver for the global blood clotting factors market. These conditions require regular administration of clotting factors to prevent excessive bleeding and manage the symptoms. Increased awareness about bleeding disorders and advancements in diagnostic techniques have led to improved identification and diagnosis of these conditions. This has resulted in a higher demand for blood clotting factors as more patients are being diagnosed and treated.

• Research and Development Proficiencies

Rising expenditure for research and development proficiencies especially in the developed and developing economies pertaining to the pharmaceutical drugs and various diagnosis methods will further create lucrative market growth opportunities. Research and development proficiencies being conducted for the integration of advanced technologies in the healthcare facilities is also bolstering the market growth rate.

• Growing Investment for Healthcare Facilities

Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

• Expansion of the Pharmaceutical Industry

The pharmaceuticals industry is experiencing growth due to various factors, including advancements in device development, increasing investments in research and development, and expanding healthcare infrastructure. This growth directly impacts the global blood clotting factor market.

• Government Investments on Healthcare Infrastructure

The increase in the funding by the federal government is set to drive the market growth rate. Moreover, growth and expansion of healthcare industry being driven by both public and private players especially in the developing economies will create lucrative market growth opportunities. Also, high return on investments assured by the research activities will also work in the favor of the market.

Restraints/Challenges

• Rising Competition

The global blood clotting factor market is highly competitive, with numerous companies offering a wide range of products. This can make it challenging for new entrants or smaller companies to gain market share and establish a strong presence.

• High Cost associated with Drug Development and Distribution

The cost of drug development and its distribution is very high in the market. Healthcare systems and payers face cost pressures, and there is a growing demand for cost-effective solutions. Manufacturers need to balance the development of innovative implants with affordability to meet market demands.

This global blood clotting factor market  report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global blood clotting factor market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In May 2021, Octapharma announced the completion of patient enrollment for a Phase 3 clinical trial evaluating the safety and efficacy of its investigational recombinant von Willebrand factor (rVWF) for the treatment of von Willebrand disease
• In March 2021, CSL Behring received approval from the U.S. Food and Drug Administration (FDA) for its IDELVION® Coagulation Factor IX (Recombinant), Albumin Fusion Protein for the treatment of hemophilia B in pediatric patients

Global Blood Clotting Factor Market Scope

The global blood clotting factor market is segmented on the basis of product, test, technology, application, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Clinical Laboratory Analysers
• Consumables
• Systems
• Automated Systems
• Semi-Automated Systems
• Manual Systems
• Point-Of-Care Testing Analysers

Test

• Prothrombin Time Testing
• Fibrinogen Testing
• Activated Partial Thromboplastin Time Testing
• Activated Clotting Time Testing
• D-Dimer Testing
• Platelet Function Tests
• Anti-Factor Xa Tests
• Heparin and Protamine Dose Response Tests for ACT
• Others

Technology

• Mechanical Technology
• Optical Technology
• Electrochemical Technology
• Others

Application

• Bleeding Disorders
• Acquired Bleeding Disorders
• Von Willebrand Disease
• Haemophilia

End User

• Academic Institutions
• Hospitals
• Diagnostic Laboratories
• Others

Global Blood Clotting Factor Market Regional Analysis/Insights

The global blood clotting factor market is analysed and market size insights and trends are provided by country, product, test, technology, application and end user as referenced above.

The countries covered in the global blood clotting factor market  report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the global blood clotting factor market because of the strong base of healthcare facilities, strong presence of major players in the market, and rising number of research activities in this region.   

Asia-Pacific is expected to witness significant growth in the global blood clotting factor market during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in healthcare facilities, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global blood clotting factor market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global blood clotting factor market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global blood clotting factor market. The data is available for historic period 2015-2020.

Competitive Landscape and Global Blood Clotting Factor Market Share Analysis

글로벌 혈액 응고 인자 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 제공된 위의 데이터 포인트는 글로벌 혈액 응고 인자 시장과 관련된 회사의 초점에만 관련이 있습니다.

글로벌 혈액 응고 인자 시장에서 활동하는 주요 기업은 다음과 같습니다.

• CSL 베링(호주)
• 샤이어(아일랜드)
• 노보노디스크(덴마크)
• 그리폴스(스페인)
• 옥타파마(스위스)
• 파이저 주식회사(미국)
• Ferring Pharmaceuticals (스위스)
• 케드리온 바이오파마(이탈리아)
• Bayer AG(독일)
• BioMarin Pharmaceutical (미국)
• 산퀸(네덜란드),
• LFB 그룹(프랑스)
• 바이오 제품 연구소(영국)
• 화란생물공학(중국)
• GC파마(한국)

SKU-46717